Predictors of Refractory Primary Chronic Rhinosinusitis Following Endoscopic Sinus Surgery
- 9 September 2026
- journal article
- research article
- Published by Wiley in International Forum of Allergy & Rhinology
Abstract
Background: Refractory chronic rhinosinusitis (CRS) after functional endoscopic sinus surgery (FESS) has traditionally been defined by revision surgery alone. With the emergence of biologic therapies, treatment escalation now includes revision surgery and/or biologic initiation. We sought to identify independent predictors of refractory primary CRS using a composite outcome incorporating surgery and/or biologic initiation. Methods: Adult patients with primary CRS undergoing FESS after 2015 were identified in the TriNetX Research Network. Patients with secondary CRS, prior biologic therapy, or sinonasal neoplasms were excluded. The primary outcome was refractory CRS, defined as revision FESS or biologic initiation from 3 months to 5 years postoperatively. Preoperative covariates were evaluated using Cox proportional hazards modeling with stepwise selection. Results: Among 24,759 patients, 2866 (11.6%) had refractory CRS after FESS. Of these, 66.6% underwent revision FESS, 42.0% initiated biologic therapy, and 8.7% had revision surgery and initiated a biologic therapy. In multivariable analysis, asthma was the strongest predictor (HR 2.06, p < 0.001), followed by allergy to analgesic agents (e.g., NSAIDs) (HR 1.87, p < 0.001), nasal polyps (HR 1.67, p < 0.001), food allergy (HR 1.37, p = 0.096), COPD (HR 1.27, p = 0.006), eosinophilia (HR 1.27, p < 0.001), and Black or African American race (HR 1.16, p = 0.044). Conclusion: Refractory CRS following FESS is strongly associated with type 2 inflammatory comorbidities and select demographic factors. Incorporating biologic therapy into outcome definitions provides a contemporary framework for risk stratification and postoperative counseling.Keywords
This publication has 63 references indexed in Scilit:
- Clinical Practice Guideline: Adult Sinusitis UpdateOtolaryngology–Head and Neck Surgery, 2025
- Clinical Practice Guideline: Surgical Management of Chronic RhinosinusitisOtolaryngology–Head and Neck Surgery, 2025
- Clinical Control and Quality of Life in Patients With Chronic Rhinosinusitis With Asthma: A Study on the Effects of Endoscopic Sinus SurgeryOtolaryngology–Head and Neck Surgery, 2024
- Revision Rates and Symptom Trends Following Endoscopic Sinus Surgery: Impact of Race on OutcomesThe Laryngoscope, 2023
- Race and ethnicity define disparate clinical outcomes in chronic rhinosinusitisAnnals of Allergy, Asthma & Immunology, 2022
- Oral Corticosteroids Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis Without Nasal PolyposisJAMA Otolaryngology–Head & Neck Surgery, 2021
- Biologics for chronic rhinosinusitisCochrane Database of Systematic Reviews, 2021
- Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta‐analysis of risk factorsInternational Forum of Allergy & Rhinology, 2019
- The relationship between allergy and chronic rhinosinusitisLaryngoscope Investigative Otolaryngology, 2018
- Revision rates and time to revision following endoscopic sinus surgery: A large database analysisThe Laryngoscope, 2017